D-0516-2019 Class III Terminated
FDA drug recall D-0516-2019 was initiated by Amerigen Pharmaceuticals Inc. on Feb 19, 2019 and is designated Class III. Reason for recall: Failed dissolution specifications The recall status is terminated (terminated Dec 17, 2019). Affected quantity: a) 2,413 bottles b) 3,355 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 27, 2019
- Initiation Date
- Feb 19, 2019
- Termination Date
- Dec 17, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 2,413 bottles b) 3,355 bottles
Product description
Temozolomide Capsules, 5 mg, packaged in a) 5-count bottle (NDC 43975-252-05) b) 14-count bottle (NDC 43975-252-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071
Reason for recall
Failed dissolution specifications
Distribution pattern
Product was distributed to 4 wholesalers/distributors and 1 retail account who may have further distribute the product throughout the United States.
Code information
Lot #: a) 18J043A, Exp 09/30/2020, b) 18J043B, Exp 09/30/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0516-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026